drugset
drugset / Trial / NCT05046808

Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects

NCT05046808 ↗

Phase 1 Completed 70 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelBasic science

Summary

This is a single-center, randomized, open-label study to compare the pharmacokinetic profiles of Famitinib and its metabolite SHR116637 at different doses/specifications.

Timeline

Start
2021-09-23
Primary completion
2021-10-08
Completion
2021-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Famitinib Small molecule 10 mg —
Subject Famitinib Small molecule 15 mg —
Subject Famitinib Small molecule 20 mg —
Subject Famitinib Small molecule 25 mg —

Indications

cancer